Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Joseph Douglas Lyon Sells 500 Shares

Corcept Therapeutics Incorporated (NASDAQ:CORTGet Free Report) insider Joseph Douglas Lyon sold 500 shares of Corcept Therapeutics stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $26.01, for a total value of $13,005.00. Following the completion of the sale, the insider now directly owns 7,314 shares in the company, valued at approximately $190,237.14. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Joseph Douglas Lyon also recently made the following trade(s):

  • On Friday, February 16th, Joseph Douglas Lyon sold 1,000 shares of Corcept Therapeutics stock. The shares were sold at an average price of $26.00, for a total value of $26,000.00.

Corcept Therapeutics Price Performance

CORT opened at $25.65 on Thursday. The business has a fifty day simple moving average of $23.49 and a 200 day simple moving average of $26.07. The company has a market capitalization of $2.66 billion, a PE ratio of 27.00 and a beta of 0.48. Corcept Therapeutics Incorporated has a 1 year low of $20.87 and a 1 year high of $34.28.

Corcept Therapeutics (NASDAQ:CORTGet Free Report) last announced its quarterly earnings data on Thursday, February 15th. The biotechnology company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.03. The firm had revenue of $135.41 million during the quarter, compared to analysts’ expectations of $129.27 million. Corcept Therapeutics had a return on equity of 21.98% and a net margin of 21.86%. The company’s quarterly revenue was up 31.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.14 EPS. Equities analysts anticipate that Corcept Therapeutics Incorporated will post 0.92 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Corcept Therapeutics

A number of institutional investors have recently modified their holdings of CORT. FinTrust Capital Advisors LLC acquired a new position in shares of Corcept Therapeutics during the 3rd quarter worth $27,000. Lazard Asset Management LLC acquired a new position in shares of Corcept Therapeutics during the 2nd quarter worth $28,000. Pinebridge Investments L.P. acquired a new position in shares of Corcept Therapeutics during the 2nd quarter worth $31,000. FNY Investment Advisers LLC acquired a new position in shares of Corcept Therapeutics during the 4th quarter worth $32,000. Finally, Gladius Capital Management LP acquired a new position in shares of Corcept Therapeutics during the 4th quarter worth $36,000. Institutional investors and hedge funds own 93.61% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on CORT shares. Truist Financial lifted their target price on Corcept Therapeutics from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Friday, February 16th. StockNews.com upgraded Corcept Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 24th. Canaccord Genuity Group lifted their target price on Corcept Therapeutics from $37.00 to $38.00 and gave the stock a “buy” rating in a research note on Wednesday, December 13th. Finally, HC Wainwright reduced their target price on Corcept Therapeutics from $34.00 to $28.00 and set a “buy” rating for the company in a research note on Tuesday, January 2nd. Two research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Corcept Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $33.79.

Read Our Latest Stock Report on Corcept Therapeutics

About Corcept Therapeutics

(Get Free Report)

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

Featured Articles

Insider Buying and Selling by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.